CD8A and B-cell chronic lymphocytic leukemia: Similarly, we found differences in the CD3+CD8-TCRγδ+ population, with levels significantly higher in Basal sample in treated CLL participants compared to those in W&W (3.2-fold; p=0.0043) and healthy donor groups (2.9-fold; p=0.0175) (Figure 4D).